Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof

Abstract

The invention concerns a composition containing at least an alkanolamide, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an oxazolin, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular its use for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such a composition on the skin and/or mucosa.

1 . Composition comprising an excipient adapted for administration by an external topic method and at least one active compound to inhibit migration of Langerhans cells chosen from the group of alkanolamides satisfying the following general formula:  
       
         
           
           
               
               
           
         
       
       in which R 1  represents an alkyl group in C 1 -C 40  comprising 0 to 6 unsaturations and possibly comprising at least one substitute chosen from the group formed by hydroxyl radicals (OH), alkoxy radicals in C 1 -C 6  (OC 1 -C 6 ) and carbonyl alkoxy radicals in C 1 -C 6  (COOC 1 -C 6 ); 
 R′ and R″ independently represent a hydrogen atom, a methyl group, a hydroxyl group, an alkyl group in C 2 -C 20  comprising 0 to 6 unsaturations and possibly comprising at least one substitute chosen from the group formed by hydroxyl radicals (OH) and alkoxy radicals in C 1 -C 6  (OC 1 -C 6 ), provided that when R′ represents a hydroxyl group, R″ represents a hydrogen or an alkyl group in C 1 -C 6  comprising from 0 to 3 unsaturations and possibly at least one substitute chosen from the group formed by hydroxyl radicals (OH), alkoxy radicals in C 1 -C 6  (OC 1 -C 6 ) and carbonyl alkoxy radicals in C 1 -C 6  (COOC 1 -C 6 );  
 R 2  represents a hydrogen atom, a methyl group, an alkyl group in C 2 -C 20  comprising 0 to 6 unsaturations and possibly at least one substitute chosen from the group formed by hydroxyl radicals (OH), alkoxy radicals in C 1 -C 6  (OC 1 -C 6 ) and carbonyl alkoxy radicals in C 1 -C 6  (COOC 1 -C 6 ).  
 
     
     
         2 . Composition according to  claim 1 , characterised in that R 1  represents a linear alkyl group saturated in C 2 -C 40 , advantageously in C 6 -C 22 , even more advantageously in C 8 -C 18 , and even more advantageously in C 10 -C 16 ; and/or 
 R′ and R″ independently represent a hydrogen atom, a methyl group or a linear alkyl group saturated in C 2 -C 20 ; and/or    R 2  represents a hydrogen atom, a methyl group or a linear alkyl group saturated in C 2 -C 20 .    
     
     
         3 . Composition according to  claim 1  or  2 , characterised in that the said alkanolamide is the alkanolamide called AK100 with the following formula:  
       
         
           
           
               
               
           
         
       
     
     
         4 . Composition according to any one of  claims 1  to  3 , characterised in that it also comprises at least one inhibitor of metalloproteases advantageously selected from the group consisting of tissue inhibitors of metalloproteinases, alpha-2-macroglobuline, plasminogen activator inhibitors, zinc chelating agents, bryostatine-1, antibiotics, synthetic or natural peptides with a structure similar to the structure of substrates of MMPs, retinoids, antioxidants, anti-cancer agents, malt hydrolysates, extracts of marine algae, shark cartilage extracts and peptide extracts of lupin.  
     
     
         5 . Composition according to  claim 4 , characterised in that the said inhibitor of MMPs is chosen from the group composed of peptide extracts of lupin, preferably extract B (LU105).  
     
     
         6 . Composition according to  claim 4 , characterised in that the said inhibitor of MMPs is chosen from the group composed of retinoids.  
     
     
         7 . Composition according to any one of  claims 1  to  3 , characterised in that it also includes at least one compound chosen from the group composed of PKC inhibitors, anti-inflammatory agents, soothing agents, immunosuppressors, ion chelating agents, oxazolines, oxazolidinones and derivatives of carbamic acid.  
     
     
         8 . Composition according to any one of the above claims, characterised in that the concentration in alkanolamide is between approximately 0.001 and approximately 10% by weight, compared with the total weight of the composition.  
     
     
         9 . Composition according to any one of the above claims for its use as a medicine.  
     
     
         10 . Use of at least one alkanolamide as defined in any one of  claims 1  to  3  or a composition according to any one of  claims 1  to  8  for preparation of a medicine intended to inhibit migration of dendritic cells, dermal dendrocytes, monocytes, lymphocytes, keratinocytes, mastocytes and endothelial cells.  
     
     
         11 . Use according to  claim 10 , characterised in that the medicine is intended to inhibit migration of Langerhans cells.  
     
     
         12 . Use according to  claim 10 , characterised in that the medicine is intended for the treatment or prevention of allergic and/or inflammatory and/or irritative reactions of the skin and/or mucosa.  
     
     
         13 . Use according to  claim 10 , characterised in that the medicine is intended for the treatment or prevention of reactions or pathologies of the skin and/or mucosa, following migration of Langerhans cells induced by a danger signal.  
     
     
         14 . Use according to  claim 10 , characterised in that the medicine is intended for the treatment or prevention of reactions or pathologies induced by chemical or metallic haptens.  
     
     
         15 . Use according to  claim 10 , characterised in that the medicine is intended for the treatment or prevention of sensitive and/or reactive and/or uncomfortable and/or intolerant skin and/or mucosa, and/or skin and/or mucosa exhibiting a barrier disorder and/or exhibiting an immunologic imbalance related to intrinsic aging, extrinsic aging or hormonal aging.  
     
     
         16 . Use according to  claim 10 , characterised in that the medicine is intended for the treatment or prevention of atopic eczema and/or contact eczema, inflammatory dermatitis such as psoriasis, irritative dermatitis, auto-immune diseases, photo-immuno-suppression or graft rejection.  
     
     
         17 . Use according to  claim 10 , characterised in that the medicine is intended to reduce the allergising and/or irritant nature of a composition or a perfume.  
     
     
         18 . Cosmetic method for the treatment of sensitive, irritated, intolerant or allergy-prone skin and/or mucosa, or aging skin and/or mucosa, to which a danger signal is applied, exhibiting a skin barrier disorder, with skin rashes or exhibiting non-pathological immunologic imbalance, related to intrinsic aging, extrinsic aging or hormonal aging, characterised in that it consists of applying a composition according to  claims 1  to  8  or at least one active compound chosen from the alkanolamides group as defined in any one of  claims 1  to  3 , to the skin and/or mucosa.